Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 14.24B +113.7% |
| Revenue (ttm) | 4.44B +9.2% |
| Net Income | 29.45M -93.9% |
| EPS | 0.47 -93.7% |
| Shares Out | 62.74M |
| PE Ratio | 483.25 |
| Forward PE | 9.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 770,224 |
| Open | 230.87 |
| Previous Close | 230.59 |
| Day's Range | 225.55 - 231.78 |
| 52-Week Range | 105.00 - 243.32 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 255.95 (+12.81%) |
| Earnings Date | Aug 4, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price target is $255.95, which is an increase of 12.81% from the latest price.
News
Jazz announces eleven presentations at SLEEP 2026
Jazz Pharmaceuticals (JAZZ) announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav oral solution in patients wi...
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaning...
Jazz Pharmaceuticals lung cancer drug fails main trial goal
Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study, potentially risking its current regulatory status.
Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint
Jazz Pharmaceuticals (JAZZ) announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca in patients with relapsed metastatic small cell lung cancer. The trial...
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, ...
Jazz Pharmaceuticals price target raised to $307 from $281 at BofA
BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $307 from $281 and keeps a Buy rating on the shares. After having surveyed 15 oncologists to gauge planned…
Jazz Pharmaceuticals assumed with a Buy at Truist
Truist assumed coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating with a price target of $256, up from $230. The firm sees near-term upside for Jazz with Ziihera’s first-line…
Jazz Pharmaceuticals Proxy statement: Proxy filing
Jazz Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Jazz Pharmaceuticals Proxy statement: Proxy filing
Jazz Pharmaceuticals filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors onl...
Jazz Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company has evolved into a diversified biopharma, advancing key assets in oncology and neuroscience, with zanidatamab showing strong clinical and regulatory momentum. Multiple pivotal trials and strategic partnerships are underway to expand indications and market reach.
Jazz Pharmaceuticals Proxy statement: Proxy filing
Jazz Pharmaceuticals filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Jazz Pharmaceuticals Phase 3 HERIZON-GEA-01 results published in NEJM
The company states: “Jazz Pharmaceuticals (JAZZ) announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safe...
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing co...
Jazz Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Zanidatamab is advancing toward potential approval in frontline GEA with a PDUFA date of August 25th, supported by strong clinical data and broad label potential. Expansion into breast cancer and other tumor types is ongoing, while ZEPZELCA's frontline launch in small cell lung cancer is driving revenue growth.
Jazz Pharmaceuticals price target raised to $253 from $234 at Barclays
Barclays raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $253 from $234 and keeps an Overweight rating on the shares. An expert call indicates Jazz has “robust” patent…
Jazz Pharmaceuticals price target raised to $301 from $232 at Piper Sandler
Piper Sandler raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $301 from $232 and keeps an Overweight rating on the shares. Jazz shares, in the firm’s view, have…
Bernstein starts Jazz at Market Perform, says clock ticking on blockbuster drugs
Bernstein initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Market Perform rating and $229 price target The firm believes investors should pass on Jazz because the current share price gives…
Jazz Pharmaceuticals initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Market Perform rating and $229 price target
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Jazz Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Zanidatamab shows strong efficacy and differentiation in HER2-positive cancers, with robust survival data and synergy with immunotherapies. Commercial teams are ready for launch, and expansion into new indications and partnerships is underway. The company also advances its sleep, epilepsy, and rare disease franchises.
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
UBS analyst Ashwani Verma upgraded Jazz Pharmaceuticals (JAZZ) to Buy from Neutral with a price target of $307, up from $188. The firm cites improved confidence in Jazz’s base business…
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC ...
Jazz Pharmaceuticals price target raised to $245 from $226 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $245 from $226 and keeps an Overweight rating on the shares.
ALX Oncology evorpacept combination data presented at ESMO congress
ALX Oncology (ALXO) announced that data from exploratory analyses in the Phase 1b/2 clinical trial evaluating the company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceu...